Anti-human immunodeficiency virus activity, bioavailability and drug resistance profile of the novel proteinase inhibitor MDL 74,695

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 3, 1997, Pages 205-214

  Taylor, D L ^a   Ahmed, P S ^a   Brennan, T M ^a   Bridges, C G ^a   Tyms, A S ^a   Van Dorsselaer, V ^b   Tarnus, C ^b   Hornsperger, J M ^b   Schirlin, D ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SANOFI   (France)

Author keywords

bioavailability; drug resistance; HIV proteinase inhibitor; HIV 1; MDL 74,695

Indexed keywords

ALANINE; DIDANOSINE; GLYCINE; INDINAVIR; ISOLEUCINE; LAMIVUDINE; MDL 74695; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VALINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESISTANCE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030966640     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800304     Document Type: Article

References (57)

1. Anon (1996) New drugs for HIV infection. Medical Letters Drugs Therapy 38: 35-37.
2. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG & Moss B (1990) An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proceedings of the National Academy of Sciences, USA 87: 7472-7476.
3. Bowman WC & Rand MJ (1980) Textbook of Pharmacology. Oxford: Blackwell Science, pp.4044-4058.
4. Brennan TM, Taylor DL, Bridges CG, Leyda JP & Tyms AS (1995) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Research 26: 173-187.
5. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C & Corey L (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. New England Journal of Medicine 334: 1011-1017.
6. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ & Emini E (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
7. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA & Mills JS (1991) Antiviral properties of Ro-31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Research 16: 295-305.
8. Craig JC, Whittaker L, Duncan IB & Roberts N (1993) In vitro resistance to an inhibitor of HIV proteinase (Ro-31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chemistry and Chemotherapy 4: 335-339.
9. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, Garcia de Lomas J, Delgado R, Borleffs JCC, Hsu A, Valdes JM, Boucher CAB & Cooper DA for the European-Australian Collaborative Ritonavir Study Group (1995) A short-term study of the safety, pharmocokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. New England Journal of Medicine 333: 1528-1533.
10. Darke PL, Nutt RF, Brady SF, Gaesky VM, Cicerone T, Leu C-T, Lumma PK, Friedinger RM, Veber DF & Sigal IS (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochemical and Biophysical Research Communications 156: 297-303.
11. Debouck C (1992) The HIV-1 protease as a therapeutic target for AIDS. AIDS Research and Human Retroviruses 8: 153-164.
12. DesJarlais RL, Seibel GL, Kuntz ID, Furth PS, Alavrez JC, Ortiz de Montellano PR, DeCamp DL, Babe LM & Craik CS (1990) Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proceedings of the National Academy of Sciences, USA 87: 6644-6648.
13. Dianzani F, Antonelli G, Turriziani O, Riva E, Dong G & Bellarosa D (1993) In vitro selection of human immunodeficiency virus type 1 resistant to Ro-31-8959 proteinase inhibitor. Antiviral Chemistry and Chemotherapy 4: 329-333.
14. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini, EA, Schleif WA & Quintero JC (1994) L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. Journal of Medicinal Chemistry 37: 3443-3451.
15. Eberle J, Bechowsky B, Rose D, Hauser U, Von der Helm K, Gurtler L, & Nitschko H (1995) Resistance of HIV type 1 to proteinase inhibitor Ro-31-8959. AIDS Research and Human Retroviruses 11: 671-677.
16. El-Farrash MA, Kuroda MJ, Kitazaki T, Masuda T, Kato K, Hatanaka M & Harada S (1994) Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-protease inhibitor. Journal of Virology 68: 233-239.
17. 2 symmetric inhibitor complexed to HIV-1 protease. Science 249: 527-533.
18. 2 symmetric protease inhibitor Journal of Virology 68: 2016-2020.
19. Hui KY, Manetta JV, Gygi T, Bowdon BJ, Keith KA, Shannon WM & Lai M-HT (1991) A rational approach in the search for potent inhibitors against HIV proteinase. FASEB Journal 5: 2606-2610.
20. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB & Mous J (1995) Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro-31-8959. Virology 206: 527-534.
21. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owen S, Andreoni M, Vella S & Mous J (1996) In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. Journal of Infectious Diseases 173: 1379-1387.
22. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW & Swanstrom R (1994) Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of viral protease. Proceedings of the National Academy of Sciences, USA 91: 5597-5601.
23. 2 symmetric inhibitors of HIV protease. Journal of Medicinal Chemistry 33: 2687-2689.
24. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong X-P, Wideburg NE, Saldivar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Hsu A, Plattner JJ, Leonard JM & Norbeck DW (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proceedings of the National Academy of Sciences, USA 92: 2484-2488.
25. King RW, Garber S, Winslow DL, Reid C, Bacheler LT, Anton E & Otto MJ (1995) Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chemistry and Chemotherapy 6: 80-88.
26. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ & Weber JN (1995) Safety and activity of saquinavir in HIV infection. Lancet 345: 952-955.
27. Kohl NE, Emini EA & Schleif WA (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proceedings of the National Academy of Sciences, USA 85: 4686-4690.
28. Koot M, Vos AHV, Keet RPM, de Goede REY, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F & Tersmette M (1992) HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6: 49-54.
29. Larder BA, Kemp SD & Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
30. Markowitz M, Saag M, Powderly WG, Hurley A, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM & Ho DD (1995a) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New England Journal of Medicine 333: 1534-1540.
31. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW & Ho DD (1995b) Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. Journal of Virology 69: 701-706.
32. Maschera B, Furfine E & Blair ED (1995) Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. Journal of Virology 69: 5431-5436.
33. McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, Sawyer TK, Heinrikson RL & Tarpley WG (1990) A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247: 454-456.
34. Meek TD, Lambert TD, Dreyer GB, Carr TJ, Tomaszek TA, Moore ML, Strickler JE, Debouck C, Hyland LJ, Matthews TJ, Metcalf BW & Petteway SR (1990) Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343: 90-92.
35. Mellors JW, Larder BA & Schinazi RF (1995) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News 3: 8-13.
36. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW & Kempf DJ (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 2: 760-766.
37. Myers G, Korber B, Wain-Hobson S, Smith RF & Pavlakis GN (1993) Human Retroviruses and AIDS 1993: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos: Los Alamos National Laboratory.
38. Otto MJ, Reid CD, Garber S, Lam PY-S, Scarnati H, Bacheler LT, Rayner MM & Winslow DL (1993a) In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrobial Agents and Chemotherapy 37: 2606-2611.
39. 2 symmetrical inhibitors of the HIV type-1 protease. Proceedings of the National Academy of Sciences, USA 90: 7543-7547.
40. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, Stuver CM, Byrn RA & Livingston DJ (1995) In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Journal of Virology 69: 5228-5235.
41. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20: 309-321.
42. Peng C, Ho BK, Chang TW & Chang NT (1989) Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. Journal of Virology 63: 2550-2556.
43. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay JK, Krohn A, Lambert RW, Morett JH, Mills, Parker KEB, Redshaw S, Ritchie AJ, Taylor DL, Thomas GJ & Machin PJ (1990) Rational design of peptide based HIV proteinase inhibitors. Science 248: 358-361.
44. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ & Merigan TC (1996) The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Annals of Internal Medicine 124: 1039-1049.
45. Schirlin D, Van Dorsselaer V, Tarnus C, Taylor DL, Tyms DL, Baltzer S, Weber F, Remy JM, Brennan TM, Farr R & Janowick D (1994) Beneficial replacement of the P1 phenylalanine side chain in HIV-1 protease inhibitors of the difluorostatone type. Bioorganic and Medicinal Chemistry Letters 4: 241-246.
46. Schneider J & Kent SBN (1988) Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV protease. Cell 54: 363-368.
47. Schramm HJ, Nakashima H, Schramm W, Wakayama H & Yamamoto N (1991) HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochemical and Biophysical Research Communications 179: 847-851.
48. Sham HL, Betebenner DA, Wideburg NE, Saldivar AC, Kohlbrenner WE, Vasavanonda S, Kempf DJ, Norbeck DW, Zhao C, Clement JJ, Erickson JE & Plattner JJ (1991) Potent HIV-1 protease inhibitors with antiviral activities in vitro. Biochemical and Biophysical Research Communications 175: 914-919.
49. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM & Blair ED (1995) Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrobial Agents and Chemotherapy 39: 1704-1710.
50. Vacca JP, Guara JP, deSohms SJ, Sander WM, Giuliani EA, Young SD, Darke PL, ZugayJ, Sigal IS, Schleif WA, Quintero JC, Emini EA, Anderson PS & Huff JR (1991) L-687,908 a potent hydroxyethylene-containing HIV protease inhibitor. Journal of Medicinal Chemistry 34: 1225-1228.
51. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, Sardana W, Schlabach AJ, Graham PI, Condra JH, Gotlib L, Holloway MK, Lin J, Chen I-W, Vastag K, Ostovic D, Anderson PS, Emini EA & Huff JR (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences, USA 91: 4096-4100.
52. Van Dorsselaer V, Schirlin D, Tarnus C, Taylor DL, Tyms DL, Weber F, Baltzer S, Remy JM, Brennan TM, Janowick D & Farr R (1994) Increased antiviral activity of HIV protease inhibitors of the difluorostatone type bearing (R)-valinol derivatives as novel C-termini. Bioorganic and Medicinal Chemistry Letters 4: 1213-1218.
53. Vella S (1994) Update on a proteinase inhibitor. AIDS 8: Supplement 3, 25-29.
54. Vella S (1995) Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 10: Supplement 1, 58-61.
55. Waynforth HB & Flecknell PA (1992) Experimental and Surgical Technique in the Rat, section 225. New York: Academic Press, pp. 230-234.
56. Williams PEO, Muirhead MJ, Madigan MJ, Mitchell AM & Shaw T (1992) Disposition and bioavailability of the HIV-proteinase inhibitor, Ro-31-8959, after single doses in healthy volunteers. British Journal of Clinical Pharmacology 34: 155.
57. Wlodawer A & Erickson JW (1993) Structure-based inhibitors of HIV-1 protease. Annual Review of Biochemistry 62: 543-585.